The market just put Neuronetics on a pedestal. The stock surged 47% today, capping a run that had already been strong over the past month, after a Q2 report that gave traders something more concrete to evaluate. The headline is margin and cash discipline. Gross margin stepped up into the low 50% range and adjusted earnings before interest, tax, depreciation and amortization flipped slightly positive as the company still reported a loss of US$3.4m.

For a historically loss making medical equipment stock, that shift in profitability trend, rather than the revenue line alone, is what is pulling sentiment sharply higher.

Is Neuronetics suddenly cheap after this margin shift, or is the lower P/S multiple just bait around a still loss making story? See how the current Q2 metrics line up in our valuation analysis for Neuronetics

Q2 2026 Earnings Summary

• Revenue, Q2 2026 vs. Q2 2025: US$41.57m vs. US$38.11m (up about 9%)
• Net Loss, Q2 2026 vs. Q2 2025: loss of US$3.44m vs. loss of US$10.12m (loss narrowed by about 66%)
• Basic EPS, Q2 2026 vs. Q2 2025: loss of US$0.05 per share vs. loss of US$0.15 per share (loss per share improved by about 69%)
• Gross Margin, Q2 2026 vs. Q2 2025: 51.1% vs. 46.6% (margin improved by 4.5 percentage points)

Prefer clear visuals instead of another wall of earnings tables and margin figures? See Neuronetics' full financial picture, including how its profitability trend fits into the bigger story, in our company report for Neuronetics.

Evaluating Neuronetics’ Profitability Turnaround Story

The bullish view on Neuronetics centers on Greenbrook and NeuroStar together building a higher margin, cash generating interventional psychiatry platform. Q2 shows early proof points. Greenbrook revenue grew faster than the group, yet group gross margin still moved into the low 50% range, so the feared drag from clinics is not dominating. Management flagged cleaner claims and better payer contracting as key drivers, which fits the thesis that revenue cycle work can offset clinic mix pressure.

On efficiency, operating expenses fell while revenue improved and adjusted EBITDA turned slightly positive at US$0.3m. That is a concrete milestone for a historically loss making business, even with a net loss of US$3.4m still in place. NeuroStar utilization among active accounts improved about 10%, suggesting referral and commercialization efforts are starting to lift throughput, even as session revenue shifts and the new go to market model is phased in.

Track how Neuronetics’ improving margins and first positive adjusted EBITDA line up against institutional expectations and whether the 47% single day share price jump has analysts raising or cutting their outlook by checking the consensus price target analysis for Neuronetics.

Neuronetics Bear Case: Profitability Steps, Cash Burn Still Looms

The core bearish claim on Neuronetics is that a structurally lower margin clinic mix, heavy operating needs and patchy cash generation could keep the business stuck in losses and dependent on the balance sheet. Q2 chips away at that, but does not retire it. Greenbrook grew faster than NeuroStar and yet group gross margin still reached 51.1%. That directly pushes back on fears that clinics would structurally cap margins in the mid 40% range. Adjusted EBITDA of US$0.3m also shows the model can at least touch breakeven.

The milestones bears care most about are still unmet. Neuronetics remains loss making with a US$3.4m net loss, full year guidance still calls for operating and investing cash outflows of US$10.5m to US$14.5m, and management is preparing investors for “choppiness” as the go to market transition plays through.

After a 47% share price jump, and with Neuronetics still loss making and not forecast to reach profitability over the next 3 years, it is worth asking whether execution risk and cash burn concerns are just beginning to surface. Review our independent risk analysis for Neuronetics which shows 2 important warning signs

Stay Ahead With Simply Wall St

If Neuronetics' sharp 47% move on its Q2 margin shift has your attention, register for free with Simply Wall St and add it to a Watchlist to track share price against fair value and watch how the profitability story develops. When you take a position, keep your focus on what really matters by using the Portfolio Command Center to cut through noise and surface only key earnings, valuation and risk updates. For a broader view on Neuronetics and other opportunities, tap into crowd insight and different viewpoints through the Community. That way you can spot potential catalysts and red flags earlier and stay a step ahead of the market.

Seeking Alternatives Beyond Neuronetics Now

Some of the most interesting stocks can move from quiet to breakout before most investors even notice. Before momentum starts flying and the edge drops, get in early.

• Spot potential breakout small caps before they are widely discussed by checking curated 21 high quality undiscovered gems that still sit under the radar for now.
• Target companies with resilient cash flows and robust balance sheets by reviewing the hand picked list of solid balance sheet and fundamentals stocks (48 results) while that quality is not fully priced in.
• Ride long term income momentum by scanning carefully filtered 9 dividend fortresses that may keep paying out even when attention shifts elsewhere, so consider reviewing them promptly.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.